Form 8-K - Current report:
SEC Accession No. 0001437749-25-014409
Filing Date
2025-05-05
Accepted
2025-05-05 08:45:10
Documents
16
Period of Report
2025-05-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250502_8k.htm   iXBRL 8-K 26663
2 EXHIBIT 99.1 ex_811025.htm EX-99.1 12553
7 a01.jpg GRAPHIC 10221
  Complete submission text file 0001437749-25-014409.txt   213829

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250505.xsd EX-101.SCH 3578
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250505_def.xml EX-101.DEF 11806
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250505_lab.xml EX-101.LAB 15857
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250505_pre.xml EX-101.PRE 12021
18 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250502_8k_htm.xml XML 2946
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 25911174
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)